Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk

Eur Heart J. 2020 Jan 7;41(2):329-330. doi: 10.1093/eurheartj/ehz853.

Authors

Niko Marx¹, Peter J Grant², Francesco Cosentino³

Affiliations

¹ Department of Internal Medicine I, University Hospital Aachen, 52074 Aachen, Germany.
² Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds/Leeds Teaching, Hospitals NHS Trust, LIGHT Laboratories, LS2 9JT Leeds, UK.
³ Cardiology Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.

PMID: 31800036
DOI: 10.1093/eurheartj/ehz853

No abstract available

Publication types

Review

MeSH terms

Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Diabetes Mellitus / drug therapy*
Glucagon-Like Peptide-1 Receptor / agonists*
Heart Disease Risk Factors
Humans
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors / pharmacology*

Substances

Glucagon-Like Peptide-1 Receptor
Sodium-Glucose Transporter 2 Inhibitors